PHAXIAM Therapeutics (XPAR:PHXM) Shares Outstanding (Basic Average): 6.57 Mil (As of Sep. 2023)


XPAR:PHXM PHAXIAM Therapeutics SA XPAR:PHXM
38 GF Score
Price €0.10
View Full Analysis

What is PHAXIAM Therapeutics Shares Outstanding (Basic Average)?

PHAXIAM Therapeutics XPAR:PHXM 38 Shares Outstanding (Basic Average) is 6.57 Mil as of Sep. 2023. GuruFocus rates XPAR:PHXM with a GF Score™ of 38/100.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. PHAXIAM Therapeutics's average basic shares outstanding for the quarter that ended in Sep. 2023 was 6.57 Mil.

PHAXIAM Therapeutics  (XPAR:PHXM) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

PHAXIAM Therapeutics Shares Outstanding (Basic Average) Related Terms

PHAXIAM Therapeutics Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Shares Outstanding (Basic Average) Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.94 1.94 1.99 2.56 3.36

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 3.36 3.36 0.36 6.57
XPAR:PHXM
38GF Score
PHAXIAM Therapeutics SA XPAR:PHXM
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 6.57 Mil mean?
PHAXIAM Therapeutics (XPAR:PHXM) has a Shares Outstanding (Basic Average) of 6.57 Mil as of Sep. 2023. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' Shares Outstanding (Basic Average) too high?
PHAXIAM Therapeutics' current Shares Outstanding (Basic Average) is 6.57 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' Shares Outstanding (Basic Average) compare to VRTX and REGN?
PHAXIAM Therapeutics' Shares Outstanding (Basic Average) of 6.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current Shares Outstanding (Basic Average) is 6.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (XPAR:PHXM) has a current Shares Outstanding (Basic Average) of 6.57 Mil. The current Shares Outstanding (Basic Average) is 6.57 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For PHAXIAM Therapeutics (XPAR:PHXM), the current Shares Outstanding (Basic Average) is 6.57 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for XPAR:PHXM

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price